PolyGlycoplex: Clinical Trials

5 trials of PolyGlycoplex, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 4, Terminated 1
Phase 22Completed 2

Follow PolyGlycoplex: new trials by email Literature Review of PolyGlycoplex trials Research Report on PolyGlycoplex

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
PolyGlycopleX® - PGX®, Rice Flour (placebo) - Type II Diabetes Mellitus, Obesity
Phase 3TerminatedInovoBiologic Inc.1002012-10-012021-02-11
Effects of a Dietary Fibre Supplementation of a Low Calorie Diet on Appetite and Body Weight
PolyGlycopleX (PGX), Rice flour - Appetite Suppression, Weight Loss
Phase 3CompletedCanadian Center for Functional Medicine202010-08-012015-10-02
Evaluation of Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX)
PolyGlycopleX (PGX) - Appetite and Hunger, Suppression, Blood Glucose, Postprandial
Phase 3CompletedCanadian Center for Functional Medicine352010-06-012015-10-02
Reduction of the Glycemic Index by a Novel Viscous Polysaccharide
PolyGlycopleX (PGX) - Blood Glucose, Postprandial
Phase 2 / Phase 3CompletedGlycemic Index Laboratories, Inc102006-05-012009-07-09
Effect of Escalating Doses of a Novel Viscous Polysaccharide on Postprandial Glycemia
PolyGlycopleX (PGX), PolyGlycopleX (PG), PolyGlycopleX - Blood Glucose, Postprandial
Phase 2 / Phase 3CompletedGlycemic Index Laboratories, Inc202006-04-012008-12-04

Conditions studied

Diabetes Mellitus, Type 2 (1)  ·  Obesity (1)  ·  Weight Loss (1)

Sponsors

Canadian Center for Functional Medicine (2)  ·  Glycemic Index Laboratories, Inc (2)  ·  InovoBiologic Inc. (1)

Countries

Canada (5)

Top investigators

Alexandra L Jenkins, PhD, RD (2)  ·  Thomas MS Wolever, MD (2)  ·  Michael Lyon, MD (1)  ·  Michael R Lyon, M.D. (1)  ·  Sean Wharton, MD, FRCPC, PharmD (1)

Results publications

PMID 21092221, PMID 23154443, PMID 32642971